Association of Interleukin-16 Polymorphisms with Graves' Disease in a Taiwanese Population

10.4077/CJP.2014.BAB150

Kun-Hsi Tsai；Ching-Yao Chang；Fuu-Jen Tsai；Hui-Ju Lin；Yuh-Shyong Yang；Yun-Ping Lim；Chiu-Chu Liao；Lei Wan

Graves' disease ； IL-16 ； polymorphisms

The Chinese Journal of Physiology

57卷2期（2014 / 04 / 30）

69 - 75

英文

Graves' disease (GD) is a complex, organ-specific autoimmune disease wherein the thyroid gland becomes enlarged and overactive. During GD progression, T cells secrete interleukin-16 (IL-16) to promote inflammation, act as chemoattractants that recruit more inflammatory cells, and activate target cells to enhance the development of GD. To investigate the role of IL-16 in GD, we genotyped 474 patients with GD at 8 single-nucleotide polymorphisms (SNPs) in the IL-16 gene. The IL-16 SNP rs8028364 was found to be associated with GD when compared with the control subjects (P = 2.93 × 10^(-17); CG genotype: odds ratio [OR] = 0.2 [0.07, 0.59]; CC genotype: OR = 0.03 [0.01, 0.09]). The rs1131445 polymorphism was found to be associated with GD under the allelic model (P = 0.01; G allele: OR = 1.97 [1.17, 3.32]). Sliding-window haplotype analysis by the PLINK program showed that the most significant haplotype was provided by the 6-SNP haplotype window, consisting of rs7182786, rs8028364, rs12907134, rs4128767, rs4072111 and rs8031107 (P = 2.31 × 10^(-51)). We found 2 protective haplotypes: GCAAGG (P = 8.69 × 10^(-7); OR = 0.22 [0.12, 0.41]) and AGAAGG (P = 0.0012; OR = 0.26 [0.12, 0.6]). In addition, GGGGAA (P = 0.39; OR = 2.32 [1.08, 4.99]) and GGGAGA (P = 1.18 × 10^(-5); OR = 5.54 [2.50, 12.31]) were found to be the two high-risk haplotypes. These results suggest that polymorphisms in IL-16 may be used as genetic markers for the diagnosis and prognosis of GD.

1. Wang, C.H.,Wu, K.H.,Yang, Y.L.,Peng, C.T.,Tsai, F.J.,Lin, D.T.,Chiu, C.F.,Lin, C.C.,Bau, D.T.(2011).Association between Ataxia Telangiectasia mutated gene polymorphisms and childhood leukemia in Taiwan.Chinese J. Physiol.,54,413-418.
   連結：
2. Adzhubei, I.A.,Schmidt, S.,Peshkin, L.,Ramensky, V.E.,Gerasimova, A.,Bork, P.,Kondrashov, A.S.,Sunyaev, S.R.(2010).A method and server for predicting damaging missense mutations.Nat. Methods,7,248-249.
3. Brix, T.H.,Kyvik, K.O.,Christensen, K.,Hegedus, L.(2001).Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts.J. Clin. Endocrinol. Metab.,86,930-934.
4. Center, D.M.,Kornfeld, H.,Cruikshank, W.W.(1996).Interleukin 16 and its function as a CD4 ligand.Immunol. Today,17,476-481.
5. Cruikshank, W.,Kornfeld, H.,Berman, J.,Chupp, G.,Keane, J.,Center, D.(1996).Biological activity of interleukin-16.Nature,382,501-502.
6. Cruikshank, W.W.,Kornfeld, H.,Center, D.M.(2000).Interleukin-16.J. Leukoc. Biol.,67,757-766.
7. Davis, R.L.,Homer, V.M.,George, P.M.,Brennan, S.O.(2009).A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.Hum. Mutat.,30,221-227.
8. de Carli, M.,D'Elios, M.M.,Mariotti, S.,Marcocci, C.,Pinchera, A.,Ricci, M.,Romagnani, S.,del Prete, G.(1993).Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy.J. Clin. Endocrinol. Metab.,77,1120-1124.
9. Gianoukakis, A.G.,Martino, L.J.,Horst, N.,Cruikshank, W.W.,Smith, T.J.(2003).Cytokine-induced lymphocyte chemoattraction from cultured human thyrocytes: evidence for interleukin-16 and regulated upon activation, normal T cell expressed, and secreted expression.Endocrinology,144,2856-2864.
10. Gu, X.J.,Cui, B.,Zhao, Z.F.,Chen, H.Y.,Li, X.Y.,Wang, S.,Ning, G.,Zhao, Y.J.(2008).Association of the interleukin (IL)-16 gene polymorphisms with Graves' disease.Clin. Immunol.,127,298-302.
11. Han, J.,Son, G.H.,Seong, J.Y.,Kim, K.(2002).GnRH pre-mRNA splicing: role of exonic splicing enhancer.Prog. Brain Res.,141,209-219.
12. Krug, N.,Cruikshank, W.W.,Tschernig, T.,Erpenbeck, V.J.,Balke, K.,Hohlfeld, J.M.,Center, D.M.,Fabel, H.(2000).Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma.Am. J. Respir. Crit. Care Med.,162,105-111.
13. Mathy, N.L.,Scheuer, W.,Lanzendorfer, M.,Honold, K.,Ambrosius, D.,Norley, S.,Kurth, R.(2000).Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes.Immunology,100,63-69.
14. Moser, B.,Willimann, K.(2004).Chemokines: role in inflammation and immune surveillance.Ann. Rheum. Dis.,63(Suppl II),ii84-ii89.
15. Moser, B.,Wolf, M.,Walz, A.,Loetscher, P.(2004).Chemokines: multiple levels of leukocyte migration control.Trends Immunol.,25,75-84.
16. Pedro, A.B.B.,Romaldini, J.H.,Takei, K.(2011).Changes of serum cytokines in hyperthyroid Graves' disease patients at diagnosis and during methimazole treatment.Neuroimmunomodulation,18,45-51.
17. Pozzoli, U.,Sironi, M.(2005).Silencers regulate both constitutive and alternative splicing events in mammals.Cell. Mol. Life Sci.,62,1579-1604.
18. Pritchard, J.,Tsui, S.,Horst, N.,Cruikshank, W.W.,Smith, T.J.(2004).Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor.J. Immunol.,173,3564-3569.
19. Uchimura, K.,Itoh, M.,Yamamoto, K.,Imamura, S.,Makino, M.,Kato, T.,Fujiwara, K.,Sawai, Y.(2002).The effects of CD40- and interleukin (IL-4)-activated CD23+ cells on the production of IL-10 by mononuclear cells in Graves' disease: the role of CD8+ cells.Clin. Exp. Immunol.,128,308-312.
20. Wang, Z.,Rolish, M.E.,Yeo, G.,Tung, V.,Mawson, M.,Burge, C.B.(2004).Systematic identification and analysis of exonic splicing silencers.Cell,119,831-845.
21. Weetman, A.P.(2000).Graves' disease.N. Engl. J. Med.,343,1236-1248.